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a group of clinicians from across europe experienced in 
the use of botulinum toxin type a for the treatment of spas-
ticity following acquired brain injury gathered to develop 
a consensus statement on best practice in managing adults 
with spasticity. this consensus table summarizes the current 
published data, which was collated following extensive lit-
erature searches, their assessment for level of evidence and 
discussion among the whole group. published information 
is supplemented by expert opinion based on clinical expe-
rience from 16 european countries, involving 28 clinicians, 
who treat an average of approximately 200 patients annu-
ally, representing many thousand spasticity treatments with 
botulinum toxin per year.
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INTRODUCTION: DEVELOPMENT OF THE 
CONSENSUS TABLE
Botulinum toxin type A is a valuable treatment in the manage-
ment of the focal problems of spasticity following acquired 
brain injury, which includes injury due to trauma, stroke, haem-
orrhage and hypoxia. This paper seeks to present a European 
consensus view on the management of adults with spasticity 
following an acute injury and was developed as a platform for 
defining and communicating the accepted best practice for the 
use of botulinum toxin type A.
This consensus statement was developed by drawing on the 
combined expertise of a number of renowned experienced users 
of botulinum toxin from 16 European countries. The process 
consisted of conducting a comprehensive literature search, 
identifying randomized controlled trials and other high-quality 
research papers, assessing the evidence, and forming consensus 
statements after extensive discussions. 
The consensus statement was divided into 10 areas: Adult 
Spasticity; Service Configuration; Treatment Options; Medico-
legal Considerations; Assessment and Goal Setting; Botulinum 
toxin type A Use and Dosage; Pharmacology of Botulinum 
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Table I. Consensus opinion
Section Key area update 
Key literature: selected clinical studies and 
reviews
Section 1: Adult spasticity following acute acquired brain injury 
Causes
• Spasticity is one feature of the UMN syndrome
• Spasticity can have a variety of causes and presentations depending on the location, age and size 
of the lesion following injury to the brain or spinal cord
• Stroke damages descending pathways involved in sensory-motor control and is a major cause of 
severe disability
• In stroke spasticity is a major feature of functional impairment
• Incidence of spasticity in stroke: 19% at 3 months to 38% at 12 months
• Early treatment of spasticity may avoid secondary mal-adaptation, functional impairment and 
loss of activity and participation
Impact – on the individual
• Impairments, e.g. pain, pressure sores, contractures depression
• Activity limitation (disability)
• Reliance on carers
• Restriction of participation
• Impaired quality of life
Impact – economically
• Financial burden on society
Healthcare systems
Social services
Loss of employment.
• Financial burden on individuals and carers.
• 38% of stroke survivors will incur ongoing costs.
Clinical studies
Incidence of spasticity after stroke (6–8)
Impact of spasticity on the individual (4, 5)
Impact of spasticity economically (16, 17)
Section 2: Service configuration
Treatment of adult spasticity must be provided by a multidisciplinary team employing a shared-care 
approach
• The rehabilitation team must be organized and supervised by a physical medicine and 
rehabilitation specialist or a neurologist specialized in rehabilitation
• Recognition and referral
Hospitals
Acquired brain injury units
General practitioners
Community healthcare professionals
Nursing homes
Relatives
Carers
• Specialist spasticity services 
Consultant physician(s) 
Physiotherapist
Occupational therapist
Nurse
Administrator
Other clinicians
• Wider teams who care for acquired brain injury patients
Acute stroke specialists
Neurologists
Neurosurgeons
In-patient departments
Out-patient departments
Professionals in community teams
Competencies required of Specialist Spasticity Services
• Trained clinicians in treatments for disabling neurological disease
• Knowledge & experience of all available spasticity treatment modalities
• Facilities to assess & treat patients
• Location 
• Space
• Equipment
• Network
Clinical papers (4, 12) 
Guidelines (community management of 
spasticity) (13, 41)
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• Referring units – virtual services
Community therapists and nurses
Surgeons
Orthopaedic surgeons – focal treatments
Neurosurgeons
Focal & segmental treatments
ITB pump placements
• Education & research activity
• Organizational commitment to accept referrals from outside
Business plan and financial security
Section 3: Treatment options for adult spasticity
Focal problems due to spasticity
• Evidence from 20 RCTs and 2 meta-analyses has demonstrated significant decreases in muscle 
tone and improved passive function (reduced impairment and improved participation) with 
botulinum toxin therapy
• There is growing evidence to show that decreasing spasticity results in active functional 
improvements, i.e. reduced activity limitation. To date there have been no randomized clinical 
trials, but improving function through reducing a stiff knee gait has been reported
• Decreased muscle tone improves possibility of functional training
• Botulinum toxin could therefore contribute to improved function
• Repeated doses of botulinum toxin produces significant improvement in activity performed and 
ability to manipulate affected limbs with reduced carer burden
• Additional studies are required that specifically address active function of the paretic limb
Botulinum toxin and shoulder pain
• Two randomized double-blind trials have demonstrated the value of botulinum toxin type A in 
relieving pain, as well as motion, in hemiplegic shoulder
• It has been suggested that this intervention is more effective than intra-articular steroid injections
Clinical studies
See Table III for details of clinical studies 
(35, 38, 42–63)
Stiff knee gait (62, 63) 
Shoulder pain clinical papers (54, 64, 65)
Section 4: Medico-legal considerations
Botulinum toxin may be used off-label
• Some treatment with botulinum toxin is off-label since in some countries it is not licensed for 
indications other than stroke and upper limb spasticity
• Reimbursement of botulinum toxin treatment in non-licensed dose and indications result in 
problems for patients and physicians accessing effective treatment in many European countries
Cost-effectiveness
• There are no formal studies of the cost-effectiveness of botulinum toxin type A and this issue 
needs to be addressed. Two papers have estimated cost indirectly
• However, the cost of stroke and complications such as fractures or pressure sores is considerable, 
so any intervention that reduces these costs will reduce the healthcare financial burden
Estimated cost of managing focal spasticity 
(16)
Cost-effectiveness of botulinum toxin 
(derived not direct studies) (15, 17)
Section 5: Assessment and goal setting
Assessment
• The specialist should assess the neurological status of patient, and should note the positive and 
negative signs of the upper motor neurone syndrome
• Confounding factors potentially influencing treatment response and post-injection treatment have 
to be considered 
Outcome measures should be based on the ICF model and be performed at the level of body 
functions and activities and participation
Goal setting
• Close cooperation between specialist team members, patient and caregivers is necessary to define 
realistic, individualized treatment goals and to achieve maximum benefit
• Goal attainment scoring may be useful in setting individual treatment goals
Clinical papers (59, 66–69)
Section 6: Botulinum toxin type A use and dosage
Botulinum toxin type A use
• Botulinum toxin treatment is one part of an integrated programme of care and should not be given 
in isolation
• While access to a multidisciplinary team is possible in the early stage of treatment, this often 
become more challenging in the long-term and care may become more fragmented with time
• Physical therapy (physical, occupational, casting, motor-training) should follow injections
• Maximum doses should not exceed:
Per injection session:
1500 MU Dysport®
600 U BOTOX® 
Clinical papers
Maximum dosing (70)
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Per injection site:
125 MU Dysport®
50 U BOTOX®
In larger muscles, multiple injection sites. Note: These dosages are based on the maximum that can be 
used safely with acceptable side-effects. They do not represent equivalent efficacy of the 2 toxins 
and cannot be used to derive a dose conversion ratio (see p. 10). Each product has to be titrated for 
each individual patient for an optimal outcome in terms of both efficacy and safety
Tolerability of botulinum toxin type A
• Doses must be assessed for each individual patient and common practice is to start at lower doses 
and titrate upwards
• A single dose study of Dysport® (1000 U vs placebo) in upper limb spasticity did not show 
significant differences in adverse events between groups
• A similar study in lower limb spasticity showed twice as many adverse events in the highest dose 
group (1500 U Dysport®) than the lower dose groups (500 and 1000 U Dysport®)
• A dose ranging study of BOTOX® (75, 100 and 300 U) in upper limb spasticity showed no 
differences in adverse events between the groups
• Single doses of 400 U of BOTOX® into calf muscles were well tolerated with no evidence of effects 
in adjacent muscles
• Further studies are needed to clarify the side-effects of high doses in adults
Tolerability of botulinum toxin (43, 51, 
52, 57)
Section 7: Pharmacology of botulinum toxin type A
Formulations of botulinum toxin type A
• To date 2 different formulations of botulinum toxin type A: BOTOX® and Dysport® have 
demonstrated efficacy in adult spasticity
 The 2 products have different manufacturing processes, formulations, structure and levels of 
homogeneity
• The 2 products use different biological assays and there is no internationally recognized dose 
comparison between the units for the different preparations
Safety of botulinum toxin A
• There is extensive clinical experience with botulinum toxin-based products
• In general, botulinum toxin type A has been shown to be efficacious and associated with few 
adverse events across many indications
• A meta-analysis of 37 studies has confirmed the good safety profile of BOTOX®
• There are differences in adverse event rates between botulinum toxin preparations, suggesting that 
use of these products should be based on individual dosing
Comparative safety
• Pre-clinical studies have shown differences in dose-response curves for safety and efficacy between 
botulinum toxin preparations, suggesting that use of these products should always be based on 
individual dosing and fixed-dose ratios should not be derived for the products
Pre-clinical papers (18, 71–74)
Clinical papers (19, 75, 76)
Meta-analysis (20) 
Section 8: Dilution and end-plate targeting
• Muscle end-plate targeting is desirable, but not always possible in human studies
• It is recommended that injections are made as near to the motor end-plates as possible, where the 
location is known. Otherwise, injections should be carried out in accordance with the available 
injection guidance charts
• In larger muscles with ill-defined or diffuse motor end-plates (e.g. soleus and gastrocnemius 
muscle), multiple injections and higher volumes may be preferable. Multiple injection sites and 
larger volumes may be impractical for small muscles
• Higher doses do not necessarily require higher volumes, so volumes can be kept low for small 
muscles
• Injection guidance is recommended for deep-seated muscles and those difficult to locate using only 
anatomical landmarks
• Patient comfort must be a consideration when considering injection volume
Pre-clinical papers (77, 78)
Clinical papers (23, 24)
Injection guidance (25–28)
Section 9: Follow-up
Long-term use of botulinum toxin type A and follow-up
• Botulinum toxin type A has shown sustained activity with repeated use up to 52 weeks and benefits 
are mainly seen in impairments
• One meta-analysis demonstrated that peak duration of response increased with time on repeated 
injections
• Decisions to repeat injections must be informed by the response to the initial treatment and the 
improvements achieved
• Follow-up is required and mechanisms should be put into place to ensure that it occurs, especially in 
the long-term
• Follow-up decisions should involve the whole team involved in the patient’s care, including the 
patient and carer
Clinical papers (12, 13, 20, 29–33, 74, 
79, 80)
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Toxin type A; Dilution and End-plate Targeting; Patient 
Follow- up; and Research Challenges.
The literature search for each of the first 9 topic areas was 
conducted using the following databases: Medline, EMBASE, 
EMBAL, BIOSIS, SciSearch, PASCAL, HCAplus and IPA. 
Clinical studies focused on randomized controlled trials or 
meta-analyses of studies that used botulinum toxin type A to 
treat spasticity resulting from acquired brain injury. Review 
articles were also included where appropriate.
A preliminary summary was compiled and presented to the 
group at a consensus meeting held in Potsdam, Germany in 
October 2007. The material was discussed and the content 
of each section revised after the meeting in the light of the 
discussions. Authors then reviewed and endorsed the content 
of the revised presentations, which provided the basis for the 
first draft of the statement. The manuscript subsequently un-
derwent review and revision by each member of the consensus 
group. The text provides a short summary of each section; the 
consensus statements are given in Table I.
ADULT SPASTICITY
This paper considers the spasticity that occurs in adults as 
a result of acute acquired brain injury due to trauma, stroke 
(including subarachnoid haemorrhage) and hypoxia. Lance’s 
definition of spasticity “a velocity-dependent increase in tonic 
stretch reflex” (1) was used as the basis for discussing the 
impact spasticity as part of the upper motor neurone (UMN) 
syndrome. 
The UMN syndrome is a well-defined concept that involves 
both positive and negative clinical phenomena (Table II) fol-
lowing damage of the central nervous sensorimotor system. 
The constellation of phenomena form a clinical pattern that 
is useful for diagnostic purposes; however, this classification 
may be regarded as somewhat out of date and inconsistent in 
terms of the underlying physiology.
Gracies (2, 3) points out that patients with spasticity form a 
clinically and physiologically recognizable population. They 
are disabled by 3 main features: (i) paresis, i.e. reduced re-
cruitment of skeletal motor units; (ii) soft tissue contracture, 
in particular muscle shortening and joint retraction; and (iii) 
muscle overactivity, i.e. reduced ability to relax muscle and 
co-contraction. These changes give rise to the commonly 
observed clinical picture of: shortened overactive muscles; 
velocity-dependent stiffness of limbs (by contrast to hypertonia 
which is not velocity dependent); loss of fine motor control; 
weakness masked by stiffness; muscle spasms; changes in 
limb posture; fatigue. 
Non-response 
• May be affected by:
Inaccurate injections
Insufficient drug dosages
Inaccurate muscle selection
Development of changes in the muscle (fibrosis, contracture, etc.)
Rarely, the formation of neutralizing antibodies
• The incidence of neutralizing antibodies following repetitive botulinum toxin type A injections 
has been calculated from retrospective data from patients with cervical dystonia. The incidence of 
antibody formation was 3% –10% with Dysport® and the old formulation of BOTOX® 
• Meta-analysis has revealed that antibody formation with current BOTOX® formulation is now a 
very rare event (1/191 adults) and is no longer considered a clinically relevant problem 
Section 10: Research challenges
Unresolved issues
• The optimal method of muscle location
• Adoption of consistent terms for describing spasticity
• The timing, duration and intensity of post botulinum toxin physical therapy
Research challenges
• Costs of treating spasticity
Multidisciplinary team costs
Cost of botulinum toxin type A vs other treatments
• Optimal trial design, including tests and clinical measures, to demonstrate functional improvements 
with botulinum toxin type A
• Optimal pre- and post-injection treatment to increase efficacy from botulinum toxin type A 
injections
UMN: upper motor neurone; ICF: international classification of functioning, disability and health; RCT; randomized controlled trial; ITB: 
intrathecal baclofen; U: units; MU: million units. 
Table II. Positive and negative phenomena of the upper motor neurone 
syndrome (81)
Positive features Negative features
• Increased tendon reflexes with 
radiation
• Clonus 
• Positive Babinski sign
• Spasticity
• Extensor spasms
• Flexor spasms
• Mass synergy patterns
• Associated reactions – stereotypic 
spastic dystonias 
• Reductions in motor activity
Weakness
Loss of dexterity
• Fatigue
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Besides acquired brain injury, the UMN syndrome also 
involves spinal cord injury, cerebral palsy and progressive 
neurological disease, but these conditions are not included in 
the current discussion as they have different clinical charac-
teristics and courses and therefore, in some aspects, require 
different treatment considerations. 
Spasticity is only one aspect of the UMN syndrome and other 
features also contribute to activity limitation and participation 
restriction. For instance, thixotropic changes in muscles, due to 
or as a consequence of spasticity, can impair people’s physical 
abilities (e.g. as a result of increased muscle stiffness) and have 
a major impact on their lifestyle. The functional consequences 
of UMN syndrome and spasticity are highly variable. The 
most affected patients are unable to perform many activities 
of daily living, resulting in poor self-care and/or difficulty 
for carers in maintaining hygiene, for example because of 
finger contractures. They become dependent on assistance 
from family members and/or carers, may have impaired social 
participation, lose self-esteem and develop a poor body im-
age. Less affected patients may present with a more limited 
movement disorder, for example equinovarus affecting gait. 
All patients may also experience pain, depression and impaired 
quality of life (4, 5). 
The incidence of troublesome spasticity requiring treat-
ment following acquired brain injury is not precisely known, 
as studies are lacking, but some have suggested that 19% of 
patients after stroke have spasticity at 3 months and 38% at 
12 months after the original trauma (6–8). Upper extremity 
hypertonia (Ashworth score > 1) was seen in 63% of patients 
with initial paralysis due to acute supratentorial stroke during 
the first 26 weeks post-stroke (9). Lacunar infarction, most 
posterior infarctions and rostrally located anterior infarctions 
do not usually give rise to spasticity (10).
However, these studies use different quantitative criteria 
to define spasticity and, when the Lance definition is used, 
almost all hemiparetic patients can be considered as having 
spasticity (2, 3).
The development of spasticity following acquired brain 
injury also does not follow a predictable pattern (9), empha-
sizing the need for organized regular assessment and, where 
necessary, a treatment plan, on an individual basis. There is a 
lack of evidence-based clinical data on spasticity assessment; 
assessment protocols are only available for stroke survivors. 
In other causes of spasticity clinical experience has shown that 
there are some more predictable sub-groups of patients, but 
currently they are poorly documented. 
SERVICE CONFIGURATION
Spasticity management must be undertaken by a multidiscipli-
nary team, since optimal treatment involves physical therapy 
in conjunction with intermittent pharmacological treatment. 
It is very important that patients are referred to spasticity or 
rehabilitation services, which essentially include clinicians 
with the necessary training, competence, expertise and facili-
ties, including space and equipment. Ta
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Guidelines for rehabilitation of adults with stroke have 
been published in the US (11). Specific guidance on the use 
of botulinum toxin therapy in the management of spasticity 
has also been published and endorsed by the Royal College of 
Physicians (UK) (12, 13) and has gained wide acceptance.
It is important that multidisciplinary teams have access to both 
secondary and primary (community) medical services, so that pa-
tients can receive the necessary physiotherapy and occupational 
therapy services. Appropriate rehabilitation programmes are 
defined for each patient with emphasis on the new rehabilitation 
techniques that exploit the neuroplasticity of the brain. 
Specialist spasticity and rehabilitation services have an 
advantage over ad hoc arrangements, in that their healthcare 
professionals have the experience and expertise of guiding 
patients to realistic and timely goals in order to achieve opti-
mal outcomes. They are also able to raise awareness amongst 
patients and carers about spasticity, the availability of new 
treatments and treatment strategies and how good referrals 
may be made to them. 
TREATMENT OPTIONS
A variety of treatment options is available and clinical ex-
perience has shown that a multi-modal approach has many 
benefits in combining physical therapies with surgical and/or 
pharmacological treatments.
There is ample evidence (12 studies in upper limb, 7 in lower 
limb, 2 mixed upper and lower limb and one meta-analysis) 
that botulinum toxin type A significantly decreases muscle 
tone and improves passive function (Table III). The demonstra-
tion of functional gains has proved more difficult (14). Some 
studies of single treatments with botulinum toxin produce 
conflicting results, which could be related to methodological 
problems in showing the improvement. However, combining 
toxin injections with physical therapy has shown functional 
improvements, lending support to the idea that this should be 
part of a comprehensive spasticity service.
MEDICO-LEGAL CONSIDERATIONS
The licensed indications for botulinum toxin type A use vary 
throughout Europe, with licensing often restricted to stroke 
and upper limb (Table IV) and much usage off-label. This 
may pose problems for patients and physicians in accessing 
effective treatment, and contributes to an inequitable access 
to specialist spasticity services across Europe.
There is a paucity of studies addressing the direct cost-
 effectiveness of botulinum toxin type A in adult spasticity. 
Three studies have been carried out using panels of physi-
cians and other healthcare professionals to provide treatment 
scenarios and anticipated improvement for typical patients 
with post-stroke spasticity (15–17). These scenarios were then 
used to calculate costs. The studies concluded that botulinum 
toxin type A gave significant benefit for little additional cost 
and, when calculated as cost per successful month of treatment 
ratio, using botulinum toxin type A actually cost less than not 
including it in the treatment regimen. These studies suggest 
therefore that botulinum toxin type A would be a cost-effective 
treatment for post-stroke spasticity.
More information is available on the costs associated with 
the complications following stroke, such as falls, fractures, 
or the pressure sores that may develop as a consequence of 
spasticity. The costs of these complications are considerable 
and will have significant impact on healthcare budgets.
Table IV. Licensed indications for botulinum toxin type A in upper limb, lower limb and hand and wrist spasticity*
Country
Spasticity hand and 
wrist following stroke Upper limb spasticity Lower limb spasticity
CommentBOTOX® Dysport® BOTOX® Dysport® BOTOX® Dysport®
Austria No No No No No No Treatment is only 
possible in hospital and 
out-patient departments
Belgium Yes Yes No Yes No No
Finland Yes No No No Only for children 
with CP
Only for children 
with CP
France, Italy, Spain, Turkey Yes Yes Yes Yes Yes Yes
Germany Yes Yes No Yes Only for pes 
equino varus in 
children with CP 
> 2 years old
No
Poland Yes Yes No Elbow Children with CP Children with CP
Switzerland Yes No Yes Post-stroke Yes No
UK Yes No Yes In conjunction 
with PT
No Only in CP
*This is not a comprehensive list of the licensed indications for botulinum toxin type A. In the majority of countries, both preparations are also 
licensed for the treatment of cervical dystonia, blepharospasm, hemifacial spasm, torticollis, pes equinus, and hyperhydrosis. There are also 
cosmetic indications for both preparations. 
CP: cerebral palsy; PT: physiotherapy.
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There is a potential risk of adverse events associated 
with distant spread of toxin and, for this reason, the sum-
mary of product characteristics (SmPC) for both Dysport® and 
BOTOX® have recently introduced some additional statements 
about patient monitoring. The SmPC for Dysport® states that 
“Side-effects related to spread of toxin distant from the site of 
administration have been reported (exaggerated muscle weak-
ness, dysphagia, aspiration/aspiration pneumonia, with fatal 
outcome in some very rare cases)”. The BOTOX® SmPC states 
“Side-effects related to spread of toxin distant from the site of 
administration have been reported, sometimes resulting in death, 
which in some cases was associated with dysphagia, pneumonia 
and/or significant debility”. All patients receiving botulinum 
toxin therapy should be advised to contact their doctor and seek 
medical attention immediately if they develop breathing, swal-
lowing, or speech difficulty or any severe allergic reaction.
ASSESSMENT AND GOAL SETTING
An essential part of treating spasticity is a proper assessment 
of the individual’s clinical status including a full neurological 
assessment, noting positive and negative signs of the UMN 
syndrome (Table II). Functional problems must be addressed 
and any confounding or exacerbating conditions, such as 
infection, pain, constipation and other nociceptive influences 
should be identified and treated (12). Treatment plans can then 
be devised on an individual basis.
The specialist will need to assess the patient, involving 
family and carer(s) fully in the planning of treatment, which 
allows the multidisciplinary management team to define re-
alistic goals and the expectation of outcomes. Briefly, these 
goals can be related to functional use, especially in the lower 
limbs; to comfort, especially in the upper limbs or proximal 
part of the lower limb; or to pain-related spasticity. 
Methods of assessing the effectiveness of treatment must 
be in place and individualized outcome measures should be 
based on the World Health Organization (WHO) International 
Classification of Functioning, Disability and Health (ICF) 
model. Assessments should be performed at regular intervals 
and continuing treatment should be refined in light of these 
assessments.
BOTULINUM TOXIN TYPE A USE AND DOSAGE
Botulinum toxin type A treatment should be given as part of 
an integrated treatment programme involving all the available 
relevant treatment modalities. Dosages are determined by the 
individual patient’s condition and the goals of treatment and 
can be reassessed according to the response. It is common 
clinical practice to initiate therapy at low, but effective, doses 
and titrate upwards as effects become evident. In order to 
have a uniform uptake of botulinum toxin within muscles, the 
muscle is injected in more than one site and this is particularly 
important in larger muscles, where the dose is divided across 
multiple sites. A single muscle is rarely treated in isolation and 
it is important that the pattern of muscle under- and over activ-
ity, at rest and while moving, is understood, so that relevant 
muscles can be treated appropriately.
As there is a lack of uniformity in terms used to describ-
ing the anatomical pattern of injections, the consensus group 
proposes that:
•	 where muscles in a close anatomical region, including only 
one or two joints (excluding finger and toe joints, e.g. hand 
and forearm or foot and ankle) are injected, the term focal 
treatment is appropriate;
•	 where several adjacent anatomical regions (e.g. hand, fore-
arm, elbow and/or shoulder) are injected, the term segmental 
treatment is appropriate;
•	 where anatomically separate and distant sites (e.g. arm and 
leg) are injected, the term multifocal or multisegmental 
treatment is appropriate. 
PHARMACOLOGY
To date, 2 formulations of botulinum toxin type A are widely 
available: BOTOX® (Allergan) and Dysport® (Ipsen); a third 
preparation, Xeomin® (Merz) has become available recently 
in some European countries, but its efficacy has not yet been 
demonstrated in adult spasticity. These preparations are manu-
factured by different processes, have different formulations and 
potencies, which are determined by different biological assays. 
This results in differences in potency of the “units” used for 
each preparation. Since there is no simple or accurate way of 
converting the unit potency of one preparation to another, it is 
important that clinicians are familiar with the characteristics 
and dosages of each preparation they use and do not try to 
convert or extrapolate from one preparation to another (18). 
Whichever preparation is used, dosages, dilutions and injec-
tions should be tailored to each individual patient.
Extensive clinical experience with botulinum toxin type 
A has shown it to be well-tolerated and associated with few 
adverse events across a variety of indications. A meta-analysis 
of 37 studies (19) has confirmed the excellent safety profile 
of BOTOX® (grade A evidence) which continues with long-
term use (20). 
An important consideration in terms of side-effects is the 
propensity for toxin to migrate away from the injection site. 
A low migration potential is desirable to restrict the action 
of the toxin to the injected muscle and minimize both local 
unwanted spread and systemic effects that could occur subse-
quent to diffusion. Clinical studies comparing the migration of 
BOTOX® and Dysport® have not been carried out in patients 
with spasticity; however, studies in both hyperhidrosis and 
cervical dystonia have concluded that BOTOX® shows less 
migration than Dysport® (21, 22). 
DILUTION, END-PLATE TARGETING AND INJECTION 
GUIDANCE
As botulinum toxin type A acts by blocking acetylcholine re-
lease at the neuromuscular junction, injection into the region 
of the motor end-plate should maximize efficacy. While some 
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muscles, such as biceps brachii, have well-defined motor end-
plates, which can be located from external landmarks (23), the 
anatomical location of the motor end-plates is unknown for 
many others. Where the end-plate location is not known, or 
for muscles with diffuse end-plates, such as the gastrocnemius 
muscle, a more even spread of injections across the muscle 
(with possibly higher injection volumes) may be necessary. 
One study has shown greater efficacy for higher dilutions of 
botulinum toxin type A when injections were not targeted to 
end-plate regions (24).
Targeting of botulinum toxin type A injections is another 
important issue. So far 2 controlled studies have shown that 
for deeply localized or small muscles needle placement based 
solely on anatomical landmarks is unsatisfactory and most 
muscles were only correctly located in less than 50% of cases 
(25, 26). Therefore injection guidance with electrical stimula-
tion or sonography for deep-seated muscles may be a better 
alternative (27, 28) and should be standard practice. A specific 
intramuscular injection into the target muscle is more effective 
and safe since the toxin is delivered to the right place; inject-
ing outside the muscle increases the potential for the toxin to 
migrate away from the target. However, muscle targeting by 
EMG or electrical stimulation, while effective, can be diffi-
cult, is time-consuming and may cause discomfort and thus is 
not always carried out in a routine clinical setting, although 
practice does vary between countries.
Patient comfort should always be a consideration in deter-
mining the number and location of injection sites and volume 
of injections as well as injection guidance techniques.
FOLLOW-UP
Botulinum toxin type A has shown sustained activity with re-
peated use for up to a year (29). The peak duration of response 
has been shown to increase with time and the interval between 
injections may also lengthen. It is important that patients are 
followed up carefully and that subsequent injection regimens 
are based on the patient’s response to previous treatment in 
terms of the gains obtained, such as increases in passive or 
active functioning.
Where there is a lack of response, the patient should be 
assessed at review to determine the possible responsible fac-
tors confounding efficacy. Inaccurate selection of the correct 
muscle, or its identification for injection, are possible causes, 
or there may have been an inadequate injection technique. 
There may be a biomechanical component of hypertonia and 
an assessment of the neural and non-neural contributions to 
muscle stiffness that could be contributing to outcome may 
be necessary. Rarely, lack of response may have been due to 
the presence of neutralizing antibodies or muscle fibrosis and 
shortening of soft tissue (e.g. ligaments and capsule). 
The incidence of neutralizing antibodies following repetitive 
botulinum toxin type A injections has been calculated from 
retrospective data from patients with cervical dystonia. The 
incidence of antibody formation was 3–10% with the old for-
mulation of BOTOX® and up to 5% with Dysport® (30–32). 
However, neutralizing antibodies are really no longer seen in 
adult spasticity treatment. As measured after the reformulation 
of BOTOX® in 1997, the formation of antibodies with this 
lower total protein preparation is now a rare occurrence, and 
deemed to be of minimal clinical significance (33).
RESEARCH CHALLENGES
Muscle identification and injection guidance
While many techniques are available to aid muscle localiza-
tion, there are no recommendations as to which techniques 
are most suitable for which muscles, nor is there concrete 
guidance as to which muscles require imaging techniques for 
accurate placement of the injections. Studies are needed to 
clarify these issues.
Cost-effectiveness
The cost-effectiveness of botulinum toxin type A has been 
estimated, but is not known with real accuracy; this is an area 
that could benefit from proper cost-efficacy studies and one 
is currently underway. 
Recommendations on pre- and post-injection treatment
Currently, there is little information on the measures that can 
modify and/or increase the efficacy of botulinum toxin injec-
tions. Electrical stimulation of the nerve or the injected muscles 
(34–36) and muscle activity itself (37) can increase efficacy of 
botulinum toxin type A. Also, physiotherapy including muscle 
stretching, casting, taping or splinting is able to act in the same 
way (38, 39). However, more studies are required to ascertain 
the optimal timing, duration and intensity of post botulinum 
toxin physical therapy and the contribution of learning proc-
esses based on repeat-attention-reward methodology (40).
Trial design
It is an acknowledged problem that designing trials and using 
clinical scales capable of demonstrating functional improve-
ments is very difficult. Attention needs to be focused on 
optimal trial design, e.g. the use or development of valid and 
sensitive clinical scales for measurement of motor control and 
functional improvements in upper and lower limb spasticity 
following botulinum toxin This assessment should follow the 
WHO’s ICF model, i.e. assess the impairment, activity limi-
tation and participation restriction; utilise the combination of 
modern physiotherapy and training methods with botulinum 
toxin treatment to elucidate the impact of reduced spasticity 
in creating a therapeutic window for employing interventions 
to produce functional improvement. 
CONCLUSION
In conclusion, botulinum toxin type A provides a valuable tool 
in the multi-modal treatment of adult spasticity. This paper 
provides a European consensus opinion on the condition and 
best practice in its treatment and defines the research chal-
lenges that still exist.
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